Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Balstilimab + Vorbipiprant |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Balstilimab | AGEN-2034|AGEN2034 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | Balstilimab (AGEN2034) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 ligand (CD274), potentially resulting in enhanced anti-tumor immune response (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3086-3086). | |
| Vorbipiprant | CR 6086|CR-6086|CR6086 | Vorbipiprant (CR6086) is an antagonist of the prostaglandin E2 receptor 4 (EP4) with potential immunomodulatory activity, and may enhance inhibition of tumor growth (PMID: 29490676, Cancer Res 2020;80(16 Suppl):Abstract nr 2208). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05205330 | Phase Ib/II | Balstilimab + Vorbipiprant | CR6086/AGEN2034 Combination in Stage IV pMMR - MSS CRC, and Other Metastatic GI Cancers | Active, not recruiting | ITA | 0 |